COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future

Horton R: The neglected epidemic of chronic disease. Lancet. 2005, 366: 1514-10.1016/S0140-6736(05)67454-5. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006, 28: 523-532. 10.1183/09031936.06.00124605. Mannino D: Chronic obstructive pulmonary disease in 2025: where are we headed?. Eur Respir J. 2005, 26: 189-10.1183/09031936.05.00063605. Annesi-Maesano I: Epidemiology of chronic obstructive pulmonary disease. Eur Respir Mon. 2006, 38: 41-70. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Maltais F, Road J, Canadian Thoracic Society: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2003. Can Respir J. 2003, 10 (Suppl A): 11A-65A. Lusuardi M, Blasi F, Terzano C, Cricelli C, Crispino N, Comarella L, De Benedetto F, Sanguinetti CM, Allegra L, Donner CF: Standards of care and clinical predictors in patients hospitalised for a COPD exacerbation - The Italian SOS (Stratification Observational Study). Monaldi Arch Chest Dis. 2009, 71: 153-160. Viegi G, Maio S, Pistelli F, Baldacci S, Carrozzi L: Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. Respirology. 2006, 11: 523-532. 10.1111/j.1440-1843.2006.00886.x. Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz D, Toren K, Viegi G: Environmental and Occupational Health Assembly, American Thoracic Society. American Thoracic Society Statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med. 2003, 167: 787-797. Salvi SS, Barnes PJ: Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009, 374: 733-743. 10.1016/S0140-6736(09)61303-9. Varkey JB, Varkey AB, Varkey B: Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Curr Opin Pulm Med. 2009, 15: 90-99. 10.1097/MCP.0b013e3283218356. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of COPD (Update 2008) Medical Communications Resources, Inc. 2008, [http://www.goldcopd.org] De Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007, 175: 32-39. Cerveri I, Corsico AG, Accordini N, Niniano R, Ansaldo E, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Svanes C, Gislason T, Heinrich J, Schouten JP, Wjst M, Burney P, de Marco R: Underestimation of airflow obstruction among young adults using FEV1/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008, 63: 1040-1045. 10.1136/thx.2008.095554. Vollmer WM, Gíslason T, Burney P, Enright PL, Gulsvik A, Kocabas A, Buist AS: Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009, 34: 588-597. 10.1183/09031936.00164608. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH: Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008, 63: 1046-1051. 10.1136/thx.2008.098483. Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR, Aldington S, Beasley R: Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009, 34: 812-818. 10.1183/09031936.00174408. ATS/ERS Standards for the diagnosis and management of patients with COPD. Accessed June 1, 2010, [http://www.thoracic.org/COPD/] Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009, 33: 1165-1185. 10.1183/09031936.00128008. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008, 31: 742-750. 10.1183/09031936.00129607. Miravitlles M, Anzueto A: Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis. 2009, 4: 185-201. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, Centanni S: The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004, 17: 35-39. 10.1016/j.pupt.2003.09.001. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009, 180: 741-750. 10.1164/rccm.200904-0492OC. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP: Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010, 137: 20-30. 10.1378/chest.09-0011. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, TORCH Clinical Endpoint Committee: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007, 62: 411-415. 10.1136/thx.2006.072348. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J: Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009, 34: 641-647. 10.1183/09031936.00193908. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF, M2-127 and M2-128 study groups: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet. 2009, 374: 695-703. 10.1016/S0140-6736(09)61252-6. Osthoff M, Leuppi JD: Management of chronic obstructive pulmonary disease patients after hospitalization for acute exacerbation. Respiration. 2010, 79: 255-261. 10.1159/000235721. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA: Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009, 179: 369-374. 10.1164/rccm.200807-1067OC. Niewoehner DE: Relation of chronic obstructive pulmonary disease exacerbations to FEV1 - an intricate tango. Respiration. 2009, 77: 229-235. 10.1159/000162877. Puhan MA, Scharplatz M, Troosters T, Steurer J: Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality: a systematic review. Respir Res. 2005, 6: 54-10.1186/1465-9921-6-54. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial: Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980, 93: 391-398. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981, 1: 681-686. National Collaborating Centre for Chronic Conditions: Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004, 59 (Suppl 1): 1-232. Eaton TE, Grey C, Garret JE: An evaluation of short-term oxygen therapy: the prescription of oxygen to patients with chronic lung disease hypoxic at discharge from hospital. Respir Med. 2001, 95: 582-587. 10.1053/rmed.2001.1106. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE, National Emphysema Treatment Trial Research Group: A randomized trial comparing lung-volumereduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003, 348: 2059-2073. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T, ATS/ERS Pulmonary Rehabilitation Writing Committee: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173: 1390-1413. 10.1164/rccm.200508-1211ST. European lung white book. Sheffield, ERS Journals Ltd. Edited by: Loddenkemper R. 2003 Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007, 370: 741-750. 10.1016/S0140-6736(07)61377-4. Mittmann N, Kuramoto L, Seung S, Haddon JM, Bradley-Kennedy C, Fitzgerald JM: The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008, 102: 413-421. 10.1016/j.rmed.2007.10.010. Chapman K, Bourbeau J, Rance L: The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003, 97 (Suppl C): S23-31. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L, Haddon J, Scalera A: Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008, 15: 13-19. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM: Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008, 63: 962-967. 10.1136/thx.2007.089557. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007, 146: 54-555. Goldstein RS, Gort EH, Guyatt GH, Feeny D: Economic analysis of respiratory rehabilitation. Chest. 1997, 112: 370-379. 10.1378/chest.112.2.370. Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P: A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J. 2004, 34: 608-614. 10.1111/j.1445-5994.2004.00672.x. Maltais F, Bourbeau J, Shapiro S, Lacasse Y, Perrault H, Baltzan M, Hernandez P, Rouleau M, Julien M, Parenteau S, Paradis B, Levy RD, Camp P, Lecours R, Audet R, Hutton B, Penrod JR, Picard D, Bernard S: Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network, Fonds de recherche en santé du Québec Effects of homebased pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008, 149: 869-878. Clark NM, Dodge JA, Partridge MR, Martinez FJ: Focusing on outcomes: making the most of COPD interventions. Int J Chron Obstruct Pulmon Dis. 2009, 4: 61-77. Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D, Bradley C: Economic benefits of self-management education in COPD. Chest. 2006, 130: 1704-1711. 10.1378/chest.130.6.1704. Rosser WW, Colwill JM, Kasperski J, Wilson L: Patient-centered medical homes in Ontario. N Engl J Med. 2010, 362: e7-10.1056/NEJMp0911519. National Heart, and Blood Institute: Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. Accessed January 18, 2010, [http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf] Croxton TL, Bailey WC: Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med. 2006, 174: 373-378. 10.1164/rccm.200507-1161WS. D'Souza AO, Smith MJ, Miller LA, Kavookjian J: An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest. 2006, 129: 1693-1708. 10.1378/chest.129.6.1693. Hilleman DE, Dewan N, Malesker M, Friedman M: Pharmacoeconomic evaluation of COPD. Chest. 2000, 118: 1278-1285. 10.1378/chest.118.5.1278. Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K, Sax M, Kaniecki DJ, Arnold RJ, Sonnenberg FA: Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study. Chest. 1993, 103: 678-684. Sclar DA, Legg RF, Skaer TL, Robison LM, Nemic NL: Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther. 1994, 16: 595-601. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ: Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999, 115: 635-641. 10.1378/chest.115.3.635. Jones PW, Wilson K, Sondhi S: Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med. 2003, 97: 20-26. 10.1053/rmed.2002.1425. Ayres JG, Price MJ, Efthimiou J: Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med. 2003, 97: 212-220. 10.1053/rmed.2003.1441. Sin DD, Golmohammadi K, Jacobs P: Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med. 2004, 116: 325-331. 10.1016/j.amjmed.2003.09.027. Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW: Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009, 103: 12-21. 10.1016/j.rmed.2008.10.005. Oba Y: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care. 2009, 15: 226-232. Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones P, Vestbo J, TOwards a Revolution in COPD Health (TORCH) investigators: Is treatment with ICS and LABA cost-effective for COPD? Multinational economicanalysis of the TORCH study. Eur Respir J. 2010, 35: 532-539. 10.1183/09031936.00153108. Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM: Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 mcg/salmeterol 50 mcg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ. 2009, 12: 339-347. 10.3111/13696990903369135. Miravitlles M, Soriano JB, García-Río F, Muñoz L, Duran-Taulería E, Sánchez G, Sobradillo V, Ancochea J: Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009, 64: 863-868. 10.1136/thx.2009.115725. Miravitlles M, Murio C, Guerrero T, Gisbert R: Costs of chronic bronchitis and COPD: a 1-year follow up study. Chest. 2003, 123: 784-791. 10.1378/chest.123.3.784. Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, Miravitlles M: Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol. 2004, 40: 72-79. Izquierdo-Alonso JL, de Miguel-Díez J: Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD. 2004, 1: 215-223. 10.1081/COPD-120039809. Bilde L, Rud Svenning A, Dollerup J, Baekke Borgeskov H, Lange P: The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls. Respir Med. 2007, 101: 539-546. 10.1016/j.rmed.2006.06.020. Dal Negro R, Berto P, Tognella S, Quareni L, Global Outcomes in Lung Disease Study Group: Cost-of-illness of lung disease in the TriVeneto region, Italy: the GOLD Study. Monaldi Arch Chest Dis. 2002, 57: 3-9. Dal Negro R, Rossi A, Cerveri I: The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med. 2003, 97 (Suppl C): S43-S50. Dal Negro R: Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2008, 3: 1-10. Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF: Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir Med. 2008, 102: 92-101. 10.1016/j.rmed.2007.08.001. Dal Negro RW, Bonadiman L, Turati C, Turco P: Clinical and pharmacoeconomic profile of COPD patients with FEV1 50-60% predicted: pilot study on the impact of the extended indication of ICS/LABA. Ther Adv Respir Dis. 2009, 3: 51-58. 10.1177/1753465809335159. De Benedetto F, Donner CF, Nardini S, Sanguinetti CM: La BPCO, la medicina respiratoria e i cambiamenti in corso nell'assistenza sanitaria. Multidisciplinary Respiratory Medicine. 2007, 2 (1): 13-15. [http://www.who.int/respiratory/gard] Donner CF, De Benedetto F, Sanguinetti CM, Nardini S: GARD-Italy launched in Rome on June 11 2009. Multidisciplinary Respiratory Medicine. 2009, 4: 272-273. Nardini S: Schiarire l'aria: uno studio nazionale sulla bronco pneumopatia cronica ostruttiva. Multidisciplinary Respiratory Medicine. 2007, 2 (1): 19-22. [http://www.healthcarecommission.gov.uk] Blumenthal D: Stimulating the adoption of health information technology. N Engl J Med. 2009, 360: 1477-1479. 10.1056/NEJMp0901592. European Commission: Competitiveness and Innovation Framework Programme (CIP). The 2008-2011 European Patients Smart Open Services project (epSOS). www.epsos.eu9. European Science Foundation. Advancing Systems Biology for Medical Applications. ESF Science Policy Briefing. 2008, 35: 1-10. Mularski RA, Asch SM, Shrank WH, Kerr EA, Setodji CM, Adams JL, Keesey J, McGlynn EA: The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest. 2006, 130: 1844-1850. 10.1378/chest.130.6.1844.